- Home
- ELLO vs DSGN Comparison
ELLO vs DSGN Comparison
Compare ELLO & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- DSGN
- Stock Information
- Founded
- ELLO 1987
- DSGN 2017
- Country
- ELLO Israel
- DSGN United States
- Employees
- ELLO N/A
- DSGN N/A
- Industry
- ELLO Electric Utilities: Central
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- DSGN Health Care
- Exchange
- ELLO Nasdaq
- DSGN Nasdaq
- Market Cap
- ELLO 208.2M
- DSGN 208.9M
- IPO Year
- ELLO 1995
- DSGN 2021
- Fundamental
- Price
- ELLO $17.00
- DSGN $3.97
- Analyst Decision
- ELLO
- DSGN Hold
- Analyst Count
- ELLO 0
- DSGN 1
- Target Price
- ELLO N/A
- DSGN $4.00
- AVG Volume (30 Days)
- ELLO 11.7K
- DSGN 104.9K
- Earning Date
- ELLO 06-30-2025
- DSGN 08-04-2025
- Dividend Yield
- ELLO N/A
- DSGN N/A
- EPS Growth
- ELLO N/A
- DSGN N/A
- EPS
- ELLO 0.43
- DSGN N/A
- Revenue
- ELLO $44,405,534.00
- DSGN N/A
- Revenue This Year
- ELLO N/A
- DSGN N/A
- Revenue Next Year
- ELLO N/A
- DSGN N/A
- P/E Ratio
- ELLO $43.83
- DSGN N/A
- Revenue Growth
- ELLO N/A
- DSGN N/A
- 52 Week Low
- ELLO $11.30
- DSGN $2.60
- 52 Week High
- ELLO $20.81
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ELLO 55.71
- DSGN 55.13
- Support Level
- ELLO $15.40
- DSGN $3.95
- Resistance Level
- ELLO $17.50
- DSGN $4.34
- Average True Range (ATR)
- ELLO 0.59
- DSGN 0.27
- MACD
- ELLO -0.10
- DSGN 0.04
- Stochastic Oscillator
- ELLO 50.96
- DSGN 73.27
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.